- Home
- NIVF vs ADXN Comparison
NIVF vs ADXN Comparison
Compare NIVF & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ADXN
- Stock Information
- Founded
- NIVF 2011
- ADXN 2002
- Country
- NIVF Thailand
- ADXN Switzerland
- Employees
- NIVF N/A
- ADXN N/A
- Industry
- NIVF
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- ADXN Health Care
- Exchange
- NIVF NYSE
- ADXN Nasdaq
- Market Cap
- NIVF 12.2M
- ADXN 11.3M
- IPO Year
- NIVF N/A
- ADXN N/A
- Fundamental
- Price
- NIVF $1.16
- ADXN $11.26
- Analyst Decision
- NIVF
- ADXN Strong Buy
- Analyst Count
- NIVF 0
- ADXN 1
- Target Price
- NIVF N/A
- ADXN $30.00
- AVG Volume (30 Days)
- NIVF 11.9M
- ADXN 24.7K
- Earning Date
- NIVF 11-16-2024
- ADXN 11-11-2024
- Dividend Yield
- NIVF N/A
- ADXN N/A
- EPS Growth
- NIVF N/A
- ADXN N/A
- EPS
- NIVF 0.21
- ADXN 0.05
- Revenue
- NIVF $5,136,153.00
- ADXN $960,641.00
- Revenue This Year
- NIVF N/A
- ADXN N/A
- Revenue Next Year
- NIVF N/A
- ADXN N/A
- P/E Ratio
- NIVF $5.39
- ADXN $1.87
- Revenue Growth
- NIVF N/A
- ADXN N/A
- 52 Week Low
- NIVF $0.55
- ADXN $5.00
- 52 Week High
- NIVF $17.24
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- ADXN 64.36
- Support Level
- NIVF $1.07
- ADXN $10.04
- Resistance Level
- NIVF $3.28
- ADXN $10.81
- Average True Range (ATR)
- NIVF 0.42
- ADXN 0.63
- MACD
- NIVF 0.05
- ADXN 0.08
- Stochastic Oscillator
- NIVF 22.42
- ADXN 86.17
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.